SynthesisWorld journal of urology2026
Peritoneal flaps for the prevention of lymphoceles after robot-assisted radical prostatectomy-a systematic review and IPD-meta-analysis of randomized controlled trials.
Synthesis in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Peritoneal interposition flaps in robot-assisted radical prostatectomy with pelvic lymph node dissection: from efficacy to optimization.World journal of urology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLymphoceles (LCs) are one of the most common complications after robot-assisted radical prostatectomy (RARP). Peritoneal flaps (PF) have shown to possibly decrease the incidence of LCs. This individual patient data meta-analysis (IPD-MA) investigates the efficacy of PF on rates of symptomatic lymphoceles (sLCs) requiring intervention, sLCs, overall lymphoceles and perioperative complications.
methodsWe conducted a prespecified systematic review and IPD-MA (PROSPERO CRD42024519284). A database search via Medline, Web of Science, Embase, Central, ClinicalTrials.gov and the International Clinical Trials Registry Platform was performed up to December 2023. Six randomized controlled trials (RCTs) comparing PF vs. no PF during RARP with PLND were included and five RCTs provided IPD. MA was conducted using a random-effects model (two-stage model).
resultsPF significantly reduced sLCs requiring intervention as well as the rates of sLCs and overall lymphoceles. Additionally, PF significantly reduced overall complications, most likely driven by fewer lymphoceles and associated interventions. Furthermore, BMI and the presence of lymphoceles at discharge were identified as risk factors for sLCs. Subgroup analyses suggested that the protective effect of PF diminishes with increasing BMI, indicating limited benefit in patients with severe obesity.
conclusionsThe creation of PF after RARP significantly reduces sLCs without affecting the complication rate or meaningfully prolonging operative time. LCs at the time of discharge represent significant risk factors for occurrence of sLCs, indicating a possibility for closer observation for this subgroup. With the evidence provided by this IPD-MA, creation of PF should be the new standard of care to reduce LC-related morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.